<DOC>
	<DOCNO>NCT01880463</DOCNO>
	<brief_summary>The VITamin D OmegA-3 Trial ( VITAL ; NCT 01169259 ) randomize clinical trial 25,875 U.S. men woman investigate whether take daily dietary supplement vitamin D3 ( 2000 IU ) omega-3 fatty acid ( Omacor fish oil , 1 gram ) reduce risk develop cancer , heart disease , stroke people prior history illness . This ancillary study conduct among participant VITAL examine whether omega-3 fatty acid vitamin D3 , compare placebo , reduce incidence and/or progression dry eye disease .</brief_summary>
	<brief_title>Dry Eye Disease Vitamin D Omega-3 Trial ( VITAL )</brief_title>
	<detailed_description>This ancillary study VITAL examine efficacy omega-3 fatty acid vitamin D3 prevention dry eye disease . The primary aim test whether omega-3 fatty acid supplementation ( 1 ) reduces incidence dry eye disease , ( 2 ) improve natural history dry eye disease relieve symptom impact quality life . Secondary aim estimate incidence dry eye disease US , prospectively examine natural history dry disease , explore factor could modify influence impact omega-3 fatty acid supplementation , evaluate interrelationship dry eye disease depression , test possible independent joint effect vitamin D3 supplementation incidence natural history dry eye disease .</detailed_description>
	<mesh_term>Keratoconjunctivitis Sicca</mesh_term>
	<mesh_term>Dry Eye Syndromes</mesh_term>
	<mesh_term>Eye Diseases</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Cholecalciferol</mesh_term>
	<criteria>All participant VITAL ( NCT 01169259 ) eligible participate ancillary study .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Dry eye disease</keyword>
	<keyword>incidence</keyword>
	<keyword>progression</keyword>
</DOC>